Loading…
Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis
We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history...
Saved in:
Published in: | Curēus (Palo Alto, CA) CA), 2022-11, Vol.14 (11), p.e31287 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593 |
container_end_page | |
container_issue | 11 |
container_start_page | e31287 |
container_title | Curēus (Palo Alto, CA) |
container_volume | 14 |
creator | Ramirez Marquez, Estefania Requejo Figueroa, Guillermo A Pappaterra-Rodriguez, Mariella Ayala Rodríguez, Sofía C Puebla, Guillermo Nieves, Ileana Oliver, Armando L |
description | We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient. |
doi_str_mv | 10.7759/cureus.31287 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9733583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2759764582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</originalsourceid><addsrcrecordid>eNpVUU1LAzEQDaKoqDfPEvBqaz52N7sXQYpfoCioeAyTbOKmtJuaZIX-e6OtRU8zzLx582YeQseUjIUom3M9BDPEMaesFlton9GqHtW0Lrb_5HvoKMYpIYQSwYggu2iPVyUtKkb30fzSzpwyQZtFwhAx4JdgIM1Nn7D1AT8b7fsWwhJPcinALFeCHyKedD44H0xyvV9A6pbY9Xn6CZL7nn1zqcMPS4ipM70DfBPg08VDtGNhFs3ROh6g1-url8nt6P7x5m5yeT_SrKrSyDJVFqBYq5WoFS9rDUS3nNtKqca2QI1qSQ0lp23BWVkVlgjbFASMaigpG36ALla8i0HNTatX0uUiuHk-RXpw8n-nd51895-yETyv45ngdE0Q_MdgYpJTP4Q-a5Ys_11URVmzjDpboXTwMQZjNxsokd_-yJU_8sefDD_5q2oD_nWDfwF_TI-V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759764582</pqid></control><display><type>article</type><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</creator><creatorcontrib>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</creatorcontrib><description>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.31287</identifier><identifier>PMID: 36514621</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Case reports ; Drug therapy ; Etiology ; Lasers ; Myasthenia gravis ; Ophthalmology ; Permeability ; Retinal detachment ; Shellfish ; Steroids ; Systemic diseases ; Tomography ; Vascular endothelial growth factor ; Visual acuity</subject><ispartof>Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31287</ispartof><rights>Copyright © 2022, Ramirez Marquez et al.</rights><rights>Copyright © 2022, Ramirez Marquez et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Ramirez Marquez et al. 2022 Ramirez Marquez et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2759764582/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2759764582?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36514621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramirez Marquez, Estefania</creatorcontrib><creatorcontrib>Requejo Figueroa, Guillermo A</creatorcontrib><creatorcontrib>Pappaterra-Rodriguez, Mariella</creatorcontrib><creatorcontrib>Ayala Rodríguez, Sofía C</creatorcontrib><creatorcontrib>Puebla, Guillermo</creatorcontrib><creatorcontrib>Nieves, Ileana</creatorcontrib><creatorcontrib>Oliver, Armando L</creatorcontrib><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</description><subject>Case reports</subject><subject>Drug therapy</subject><subject>Etiology</subject><subject>Lasers</subject><subject>Myasthenia gravis</subject><subject>Ophthalmology</subject><subject>Permeability</subject><subject>Retinal detachment</subject><subject>Shellfish</subject><subject>Steroids</subject><subject>Systemic diseases</subject><subject>Tomography</subject><subject>Vascular endothelial growth factor</subject><subject>Visual acuity</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpVUU1LAzEQDaKoqDfPEvBqaz52N7sXQYpfoCioeAyTbOKmtJuaZIX-e6OtRU8zzLx582YeQseUjIUom3M9BDPEMaesFlton9GqHtW0Lrb_5HvoKMYpIYQSwYggu2iPVyUtKkb30fzSzpwyQZtFwhAx4JdgIM1Nn7D1AT8b7fsWwhJPcinALFeCHyKedD44H0xyvV9A6pbY9Xn6CZL7nn1zqcMPS4ipM70DfBPg08VDtGNhFs3ROh6g1-url8nt6P7x5m5yeT_SrKrSyDJVFqBYq5WoFS9rDUS3nNtKqca2QI1qSQ0lp23BWVkVlgjbFASMaigpG36ALla8i0HNTatX0uUiuHk-RXpw8n-nd51895-yETyv45ngdE0Q_MdgYpJTP4Q-a5Ys_11URVmzjDpboXTwMQZjNxsokd_-yJU_8sefDD_5q2oD_nWDfwF_TI-V</recordid><startdate>20221109</startdate><enddate>20221109</enddate><creator>Ramirez Marquez, Estefania</creator><creator>Requejo Figueroa, Guillermo A</creator><creator>Pappaterra-Rodriguez, Mariella</creator><creator>Ayala Rodríguez, Sofía C</creator><creator>Puebla, Guillermo</creator><creator>Nieves, Ileana</creator><creator>Oliver, Armando L</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20221109</creationdate><title>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</title><author>Ramirez Marquez, Estefania ; Requejo Figueroa, Guillermo A ; Pappaterra-Rodriguez, Mariella ; Ayala Rodríguez, Sofía C ; Puebla, Guillermo ; Nieves, Ileana ; Oliver, Armando L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Case reports</topic><topic>Drug therapy</topic><topic>Etiology</topic><topic>Lasers</topic><topic>Myasthenia gravis</topic><topic>Ophthalmology</topic><topic>Permeability</topic><topic>Retinal detachment</topic><topic>Shellfish</topic><topic>Steroids</topic><topic>Systemic diseases</topic><topic>Tomography</topic><topic>Vascular endothelial growth factor</topic><topic>Visual acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramirez Marquez, Estefania</creatorcontrib><creatorcontrib>Requejo Figueroa, Guillermo A</creatorcontrib><creatorcontrib>Pappaterra-Rodriguez, Mariella</creatorcontrib><creatorcontrib>Ayala Rodríguez, Sofía C</creatorcontrib><creatorcontrib>Puebla, Guillermo</creatorcontrib><creatorcontrib>Nieves, Ileana</creatorcontrib><creatorcontrib>Oliver, Armando L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramirez Marquez, Estefania</au><au>Requejo Figueroa, Guillermo A</au><au>Pappaterra-Rodriguez, Mariella</au><au>Ayala Rodríguez, Sofía C</au><au>Puebla, Guillermo</au><au>Nieves, Ileana</au><au>Oliver, Armando L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2022-11-09</date><risdate>2022</risdate><volume>14</volume><issue>11</issue><spage>e31287</spage><pages>e31287-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>We report on a case of central serous chorioretinopathy (CSCR) secondary to chronic steroid use that showed sustained improvement when treated with an aflibercept intravitreal injection. A 44-year-old woman presented with decreased visual acuity of the left eye (OS). The patient had a recent history of myasthenia gravis and was being treated with systemic corticosteroids and immunosuppressants. At presentation, her visual acuity was 20/80 OS; an examination (using fluorescein angiography) of the left fundus revealed a serous retinal detachment of the posterior pole that extended to the mid-periphery and multiple areas of leakage, which findings were consistent with CSCR. The patient also had a history of unresolved strabismic amblyopia in her right eye. The patient's CSCR was managed with one injection of intravitreal aflibercept (2 mg/0.05 mL). One month following treatment, her visual acuity improved to 20/20 OS, and the serous retinal detachment had resolved. Ten months following treatment, an examination revealed a sustained improvement, with a visual acuity of 20/20 OS. Concomitantly, the patient's amblyopic eye revealed an improved visual acuity of 20/20. Our case suggests that some cases of secondary CSCR may respond to treatment with intravitreal aflibercept. This case also suggests that the CSCR imposed a unique form of occlusion therapy that helped improve the amblyopia of the contralateral eye in this adult patient.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36514621</pmid><doi>10.7759/cureus.31287</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-8184 |
ispartof | Curēus (Palo Alto, CA), 2022-11, Vol.14 (11), p.e31287 |
issn | 2168-8184 2168-8184 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9733583 |
source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
subjects | Case reports Drug therapy Etiology Lasers Myasthenia gravis Ophthalmology Permeability Retinal detachment Shellfish Steroids Systemic diseases Tomography Vascular endothelial growth factor Visual acuity |
title | Aflibercept as a Treatment for Secondary Central Serous Chorioretinopathy in a Patient With Myasthenia Gravis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T21%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aflibercept%20as%20a%20Treatment%20for%20Secondary%20Central%20Serous%20Chorioretinopathy%20in%20a%20Patient%20With%20Myasthenia%20Gravis&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ramirez%20Marquez,%20Estefania&rft.date=2022-11-09&rft.volume=14&rft.issue=11&rft.spage=e31287&rft.pages=e31287-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.31287&rft_dat=%3Cproquest_pubme%3E2759764582%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-f2b54ab2dcb78b358ca0cd33f6bb9fda1ebd08a531d432564f07f940aeb910593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2759764582&rft_id=info:pmid/36514621&rfr_iscdi=true |